Bajaj Healthcare Limited (BHL), one of the leading manufacturers of API and formulations, has announced that it has received FDA approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug and formulation for its tablets.
Hydroxychloroquine Sulphate has been recommended by several countries, including the US, with limited dosage for Covid-19 patients and as a- preventive for high-risk individuals like healthcare workers.
BHL will commence its own production of Hydroxychloroquine Sulphate API in the next 3 weeks at its state-of-art manufacturing facilities based in Vadodara, Gujarat.
Sajankumar Bajaj, Chairman & Managing Director of the Company said, “This is a very critical time in our fight against COVID-19. With our existing capabilities and our ability to fast-track production of Hydroxychloroquine Sulphate and its tablets, we are well-positioned to partially meet the prospective demand and will continue to do everything we can to support the healthcare needs of our fellow citizens and human race globally.”
India manufactures 70% of the world’s supply of Hydroxychloroquine Sulphate. As the COVID-19 pandemic widens across the world, there has been a sudden interest in an anti-malarial and anti-inflammatory drug called Hydroxychloroquine Sulphate.
Update: The original post erroneously mentioned FDA as USFDA in the post title. The same has been updated. (17 April 2020, 8 42 pm). The company has received approval from FDA Gandhi Nagar, Gujarat, India and not from USFDA.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.